Sanofi: Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease

Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris, May 28, 2026. The US Food and Drug Administration (FDA) has granted priority review to the new drug ...
The Pharma Letter

Sanofi’s venglustat accepted for priority review by FDA

The US Food and Drug Administration (FDA) has granted priority review to the new drug application (NDA) for Sanofi’s (Euronext: SAN) venglustat, a novel, investigational oral glucosylceramide synthase ...

Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease

Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher diseaseParis, May 28, 2026. The US Food and Drug ...